UPDATE: Guggenheim Initiates Horizon With Buy, $36 Target As Firm Believes Co. Is 'EV-103 data at ESMO could hint at larger opportunity in bladder cancer'; Sees 'upside to estimates on Krystexxa /Teprotumumab top line growth (we are modestly above cons.)'